Top Markets
#1 EXOD EXOD +22.08%
#2 Status Status +18.25%
#3 Ontology Gas Ontology Gas +14.98%
#4 Derive Derive +11.23%
#5 Fake World Assets Fake World Assets +9.05%
#6 aelf aelf +8.29%
#7 Anvil Anvil +5.72%
#8 Tornado Cash Tornado Cash +5.44%
#9 The Black Bull The Black Bull +5.21%
#10 B3 (Base) B3 (Base) +5.04%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
LAVA Therapeutics N.V. LAVA Therapeutics N.V.

LAVA Therapeutics N.V.

LVTX
Rank in Stocks #25847
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical... LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.
Share Price
$1.74
Last synced: 2025-11-28
Market Cap
$45.77M
Change (1 day)
0.00%
Change (1 year)
12.26%
Country
NL
Trade LAVA Therapeutics N.V. (LVTX)

Category

Healthcare
Revenue for LAVA Therapeutics N.V. (LVTX)
Revenue in Aug 2026 TTM: 0
According to LAVA Therapeutics N.V. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for LAVA Therapeutics N.V. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US